NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Provides Review of Successful 2024 Advancing the Field of Breast Cancer Treatment
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Sectors of Businessย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ January 9, 2025 โ Agendiaยฎ, Inc. today ย provided a topline review of the companyโs key Read More
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrintยฎ as the only commercially available genomic signature that may identify patient subgroups with resistance to CDK4/6 inhibition New real world evidence from FLEX adds to the growing body of Read More
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrintยฎ in predicting chemotherapy benefit for distant recurrence free interval among patients with HR+HER2-early-stage breast cancerย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 11, 2024 โ Read More
Newsroom
News, Stories & Breast Cancer Blog
Breast Cancer Statistics 2024
Authors Angela N. Giaquinto MSPH | Hyuna Sung PhD | Lisa A. Newman MD, MPH | Rachel A. Freedman MD, MPH | Robert A. Smith PhD | Jessica Star MA, MPH | Ahmedin Jemal Read More
Anthracyclines and Treatment of Early-Stage Breast Cancer
For decades, anthracyclines have played an important role in treating early-stage breast cancer. But whether this class of drugs should continue to be recommended in early disease given that other available therapies are less Read More
Improving Tailored Treatment Plans in HR+ and HER2- Early Breast Cancer
Genomic profiling in the FLEX trial predicted chemotherapy response in HR+, HER2- breast cancer, which could enable tailored treatment plans. Inย an abstractย presented at theย 2024 San Antonio Breast Cancer Symposium, researchers used genomic profiling in Read More
Healthcare Tech Outlook Named Agendia as One of the Top 10 Precision Oncology Solutions Providers in 2024
We are happy to announce Agendia has been named one of the Top 10 Precision Oncology Solutions Providers in 2024. Agendia is proud to be a part of the precision medicine movement with our Read More
What Is Neoadjuvant Chemotherapy?
If you or a loved one has been diagnosed with cancer, your care team may recommend chemotherapy, one of the most common types of cancer treatment available. Chemotherapy involves the use of medications that Read More
What Can We Learn From A Highly Diverse Observational Study Of 17,000+ Breast Cancer Patients?
A conversation with Agendia CMO William Audeh, MD More than 17,000 patients have enrolled in Agendiaโs FLEX trial studying full genome profiling and complete clinical data for those diagnosed with stages I, II, or Read More
How Agendia is personalizing breast cancer treatment
By Abbey Bowling | October 29, 2024 October is Breast Cancer Awareness Month, andย Agendia, one of the leading providers in the field of precision oncology is working to make a significant impact in Read More